Medivir AB (STO:MVIRB), a research-based pharmaceutical company with a focus on oncology, announced on Thursday that its nomination committee will propose to the Annual General Meeting 2018 that a new board of directors is appointed through the re-election of current board members Anders Hallberg, Bengt Julander, Helena Levander, Anna Malm Bernsten and Bengt Westermark, with Bernsten proposed for re-election as chairman of the board.

Uli Hacksell and Lennart Hansson are proposed as new board members. Reportedly, Anders Ekblom has declined re-election.

Hacksell most recently was CEO of ACADIA Pharmaceuticals between 2000 – 2015. Prior to that, he has held various senior executive positions at Astra AB and has held the position of professor in organic chemistry at Uppsala University. He is chairman of the board of Cerecor Inc and a board member of InDex Pharmaceuticals AB, Beactica AB and Uppsala University.

Hansson is currently a senior advisor at Industrifonden. He has experience from the life science sector with leading and executive positions from KabiGen AB, Symbicom AB, AstraZeneca, Arexis AB, Biovitrum AB and Karolinska Development AB. He is a board member of InDex Pharmaceuticals AB, Athera Biotechnologies AB, Ignitus AB (chairman), Calliditas Therapeutics AB, Sixera Pharma AB (chairman) and Cinclus Pharma AG.

Reportedly, Medivir's nomination committee 2017-2018 is composed of representatives for the company's three largest shareholders at the end of the third quarter of 2017, who have accepted to be part of the nomination committee, as well as the chairman of the board.

Members of the nomination committee 2017-2018 are Maria Rengefors, chairman of the nomination committee, representing Nordea Fonder;

Bo Öberg, representing the class A shareholders; Bengt Julander, representing Linc AB and Anna Malm Bernsten, chairman of the board of Medivir.